Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma

Frontiers in Oncology

Sang Soo Lee¹  Kyu-Pyo Kim²  Changhoon Yoo²  You-Na Sung³  Sung Joo Kim³  Seung-Mo Hong³  Sun-Young Jun⁴  Dae Wook Hwang⁵  Jae Hoon Lee⁵  Shin Hwang⁵ 

[1] Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;Department of Pathology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea;Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;

关键词: gallbladder;    cancer;    mismatch repair proteins;    microsatellite Instability;    HER2;   

DOI  :  10.3389/fonc.2021.658564

来源: DOAJ

【 摘 要 】

BackgroundGallbladder cancer (GBC) has a poor prognosis. Although complete surgical resection is the only successful approach for improving survival, additional therapeutic modalities are required for recurrent or surgically unresectable GBCs.Materials and MethodsTo determine the expression status of HER2 and the mismatch repair (MMR) proteins MLH1, MSH2, MSH6, and PMS2, immunohistochemical staining of MMR proteins and HER2 was carried out in 216 surgically resected GBCs. HER2 labeling was scored by adopting a scoring system for gastric carcinomas. Tissues scoring 0 to 2+ were defined as HER2 negative, whereas those scoring 3+ were regarded as HER2-positive. In addition, silver in situ hybridization and microsatellite instability (MSI) analysis were conducted to confirm HER2 amplification and MSI, respectively.ResultsThree of 216 GBCs (1.3%) showed MMR protein deficiency. All three observed MSI cases exhibited dual loss of MSH2 and MSH6 protein expression. However, no cases showed loss of either MLH1 or PMS2 expression. No association was observed between MMR protein deficiency and other clinicopathological factors. HER2 amplification was noted in 30 (13.9%) GBCs and associated with Crohn-like lymphoid reaction (P = 0.023). No survival difference was observed based on HER2 overexpression or HER2 amplification status.ConclusionMMR protein deficiency and HER2 overexpression were observed in a small subset (1.3% and 13.9%, respectively) of GBCs without simultaneous occurrence of deficient MMR protein expression and HER2 overexpression. The presence of Crohn-like lymphoid reaction may help identify cases with HER2 amplification, by using hematoxylin-stained slides. Although the proportion of MMR protein-deficient- and HER2-overexpressing GBCs was small, applying immunotherapy to MMR protein-deficient GBCs and herceptin to HER2-overexpressing GBCs may provide alternative treatment options for patients with GBC.

【 授权许可】

Unknown